MX2022008949A - Formulacion de anticuerpos estable. - Google Patents

Formulacion de anticuerpos estable.

Info

Publication number
MX2022008949A
MX2022008949A MX2022008949A MX2022008949A MX2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A MX 2022008949 A MX2022008949 A MX 2022008949A
Authority
MX
Mexico
Prior art keywords
antibody
ebov
present disclosure
storage
antibody formulation
Prior art date
Application number
MX2022008949A
Other languages
English (en)
Spanish (es)
Inventor
Dingjiang Liu
Long Xu
Yuan Cao
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022008949A publication Critical patent/MX2022008949A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2022008949A 2020-01-24 2021-01-22 Formulacion de anticuerpos estable. MX2022008949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062965786P 2020-01-24 2020-01-24
PCT/US2021/014524 WO2021150829A1 (en) 2020-01-24 2021-01-22 Stable antibody formulation

Publications (1)

Publication Number Publication Date
MX2022008949A true MX2022008949A (es) 2022-08-15

Family

ID=74858743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008949A MX2022008949A (es) 2020-01-24 2021-01-22 Formulacion de anticuerpos estable.

Country Status (13)

Country Link
US (2) US12337199B2 (cg-RX-API-DMAC7.html)
EP (1) EP4093435A1 (cg-RX-API-DMAC7.html)
JP (2) JP7674369B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131923A (cg-RX-API-DMAC7.html)
CN (1) CN115243718A (cg-RX-API-DMAC7.html)
AU (1) AU2021210942A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014240A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162569A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001989A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010254A2 (cg-RX-API-DMAC7.html)
IL (1) IL294375B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022008949A (cg-RX-API-DMAC7.html)
WO (1) WO2021150829A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112545886A (zh) 2015-03-10 2021-03-26 里珍纳龙药品有限公司 无菌刺穿系统和方法
US20200148750A1 (en) 2016-07-21 2020-05-14 Emory University Ebola Virus Antibodies and Binding Agents Derived Therefrom
CA3055583A1 (en) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injector
MX2022008949A (es) * 2020-01-24 2022-08-15 Regeneron Pharma Formulacion de anticuerpos estable.
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
WO2025171492A1 (en) 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
US20260221053A1 (en) 2025-01-29 2026-07-30 Regeneron Pharmaceuticals, Inc. Drug delivery devices, safety systems, training devices, and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
AU7089600A (en) 1999-08-30 2001-03-26 U.S. Army Medical Research Institute Of Infectious Diseases Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
EP2262832A4 (en) 2008-02-01 2011-03-09 Ca Minister Health & Welfare MONOCLONAL ANTIBODIES TO EBOLA AND MARBURG VIRUSES
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2014031718A1 (en) 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
JP6041580B2 (ja) * 2012-08-28 2016-12-14 京セラ株式会社 電子機器、制御方法、及び制御プログラム
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
SG11201909941QA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US20210054079A1 (en) * 2018-04-25 2021-02-25 Medimmune Limited Formulations of human anti-pd-li antibodies
MX2022008949A (es) * 2020-01-24 2022-08-15 Regeneron Pharma Formulacion de anticuerpos estable.

Also Published As

Publication number Publication date
EP4093435A1 (en) 2022-11-30
JP2025090691A (ja) 2025-06-17
IL294375B2 (en) 2026-06-01
CA3162569A1 (en) 2021-07-29
WO2021150829A1 (en) 2021-07-29
AU2021210942A1 (en) 2022-07-14
IL294375A (en) 2022-08-01
BR112022014240A2 (pt) 2022-12-13
US20250288665A1 (en) 2025-09-18
JP2023511080A (ja) 2023-03-16
CL2023002560A1 (es) 2024-03-01
CO2022010254A2 (es) 2022-08-09
IL294375B1 (en) 2026-02-01
US12337199B2 (en) 2025-06-24
CN115243718A (zh) 2022-10-25
KR20220131923A (ko) 2022-09-29
JP7674369B2 (ja) 2025-05-09
CL2022001989A1 (es) 2023-03-31
US20210252146A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CL2022001989A1 (es) Formulación de anticuerpos estable
PH12019502123A1 (en) Stable antibody formulation
ES2537963T3 (es) Estabilización de composiciones acuosas de proteínas con tampones de desplazamiento
CY1123909T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
PH12021552092A1 (en) Stabilized formulations containing anti-il-33 antibodies
CY1121233T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)
MX358647B (es) Formulacion liquida de insulina de accion prolongada y de peptido insulinotropico.
PH12017500844B1 (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
AU2013255457A8 (en) Lyophilised and aqueous anti-CD40 antibody formulations
MX369479B (es) Formulación líquida de un cunjugado de péptido insulinotropico de acción prolongada.
TN2009000382A1 (en) Stable antibody formulations
WO2012076670A3 (en) Antibody formulation
MY205764A (en) Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
BR112021011290A2 (pt) Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf
BR112021019612A2 (pt) Formulações, recipiente, artigo de fabricação, método para produzir a formulação e método para inibir a agregação de uma proteína presente em uma solução aquosa
ZA202204982B (en) Stable formulation of integrin antibody
EP4628092A8 (en) Insulin aspart composition (embodiments)
MX2022016403A (es) Formulaciones de anticuerpo de activina a y métodos para utilizarlas.
CY1125584T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r)
TN2012000342A1 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies